Comparison of [⁶⁸Ga]Ga-FAPI-04 PET/CT, [¹⁸F]FDG PET/CT, Enterography, and Intestinal Ultrasound in Assessing Crohn's Disease.

IF 2.5 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Biology Pub Date : 2026-02-01 Epub Date: 2025-12-05 DOI:10.1007/s11307-025-02067-4

Jieling Zheng, Hongxu Zhu, Linlin Zhang, Fuqi Xu, Chao Wang, Zenan Wu, Weibing Miao

{"title":"Comparison of [68Ga]Ga-FAPI-04 PET/CT, [18F]FDG PET/CT, Enterography, and Intestinal Ultrasound in Assessing Crohn's Disease.","authors":"Jieling Zheng, Hongxu Zhu, Linlin Zhang, Fuqi Xu, Chao Wang, Zenan Wu, Weibing Miao","doi":"10.1007/s11307-025-02067-4","DOIUrl":null,"url":null,"abstract":"Purpose: We aimed to compare the diagnostic performance of [68Ga]Ga-FAPI-04 PET/CT, [18F]F-FDG PET/CT, enterography and intestinal ultrasound (IUS) in detecting inflamed segments in patients with Crohn's disease (CD), as well as in identifying CD-related complications.Methods: This prospective study enrolled 16 patients with CD. Each patient underwent [68Ga]Ga-FAPI-04 PET/CT, [18F]F-FDG PET/CT, enterography, and IUS within 14 days. Using endoscopic results as the reference standard, we assessed the diagnostic accuracy and agreement across these imaging modalities for detecting segmental lesions in the proximal upper gastrointestinal (GI) tract and ileocolon. Their performance in identifying CD-associated complications and mesenteric changes was also evaluated.Results: [68Ga]Ga-FAPI-04 PET/CT exhibited high sensitivity (73.3%, 95% CI: 0.610-0.829), specificity (97.8%, 95% CI: 0.887-0.996) and accuracy (84.0%, 95% CI: 0.758-0.897) for detecting segmental lesions in the terminal ileum and colon. These performance metrics were comparable to those of enterography, [18F]F-FDG PET/CT and IUS (all P > 0.05), with nearly perfect diagnostic agreement observed among these imaging modalities (all κ > 0.81; all P < 0.001). In the upper GI tract and proximal small intestine, its sensitivity (53.8%, 95% CI:0.291-0.768), specificity (92.1%, 95% CI:0.792-0.973) and accuracy (82.4%, 95% CI:0.697-0.904) were similar to [18F]F-FDG PET/CT and enterography, with good diagnostic agreement (both κ = 0.73; P < 0.001). However, its resolution was suboptimal for detecting mild lesions. Notably, [68Ga]Ga-FAPI-04 PET/CT outperformed other imaging methods in detection rate and sensitivity for identifying CD-associated complications and mesenteric changes.Conclusion: [68Ga]Ga-FAPI-04 PET/CT may sever as a one-step, non-invasive diagnostic option for CD patients.","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"81-92"},"PeriodicalIF":2.5000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-025-02067-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: We aimed to compare the diagnostic performance of [⁶⁸Ga]Ga-FAPI-04 PET/CT, [¹⁸F]F-FDG PET/CT, enterography and intestinal ultrasound (IUS) in detecting inflamed segments in patients with Crohn's disease (CD), as well as in identifying CD-related complications.

Methods: This prospective study enrolled 16 patients with CD. Each patient underwent [⁶⁸Ga]Ga-FAPI-04 PET/CT, [¹⁸F]F-FDG PET/CT, enterography, and IUS within 14 days. Using endoscopic results as the reference standard, we assessed the diagnostic accuracy and agreement across these imaging modalities for detecting segmental lesions in the proximal upper gastrointestinal (GI) tract and ileocolon. Their performance in identifying CD-associated complications and mesenteric changes was also evaluated.

Results: [⁶⁸Ga]Ga-FAPI-04 PET/CT exhibited high sensitivity (73.3%, 95% CI: 0.610-0.829), specificity (97.8%, 95% CI: 0.887-0.996) and accuracy (84.0%, 95% CI: 0.758-0.897) for detecting segmental lesions in the terminal ileum and colon. These performance metrics were comparable to those of enterography, [¹⁸F]F-FDG PET/CT and IUS (all P > 0.05), with nearly perfect diagnostic agreement observed among these imaging modalities (all κ > 0.81; all P < 0.001). In the upper GI tract and proximal small intestine, its sensitivity (53.8%, 95% CI:0.291-0.768), specificity (92.1%, 95% CI:0.792-0.973) and accuracy (82.4%, 95% CI:0.697-0.904) were similar to [¹⁸F]F-FDG PET/CT and enterography, with good diagnostic agreement (both κ = 0.73; P < 0.001). However, its resolution was suboptimal for detecting mild lesions. Notably, [⁶⁸Ga]Ga-FAPI-04 PET/CT outperformed other imaging methods in detection rate and sensitivity for identifying CD-associated complications and mesenteric changes.

Conclusion: [⁶⁸Ga]Ga-FAPI-04 PET/CT may sever as a one-step, non-invasive diagnostic option for CD patients.

查看原文本刊更多论文

[68Ga]Ga-FAPI-04 PET/CT、[18F]FDG PET/CT、肠造影和肠超声诊断克罗恩病的比较

目的：比较[68Ga]Ga-FAPI-04 PET/CT、[18F]F-FDG PET/CT、肠造影和肠超声（IUS）对克罗恩病（CD）患者炎症节段的诊断价值，以及对CD相关并发症的诊断价值。方法：本前瞻性研究纳入16例CD患者，每位患者在14天内接受[68Ga]Ga-FAPI-04 PET/CT、[18F]F-FDG PET/CT、肠造影和IUS检查。使用内镜结果作为参考标准，我们评估了这些成像方式在检测近端上胃肠道和回肠节段性病变方面的诊断准确性和一致性。他们在识别cd相关并发症和肠系膜改变方面的表现也被评估。结果：[68Ga]Ga-FAPI-04 PET/CT检测回肠末端和结肠节段性病变的灵敏度（73.3%,95% CI: 0.610-0.829）、特异性（97.8%,95% CI: 0.887-0.996）和准确性（84.0%,95% CI: 0.758-0.897）均较高。这些性能指标与肠造影、[18F]F-FDG PET/CT和IUS（均P > 0.05）相当，这些成像方式之间的诊断一致性近乎完美(均κ > 0.81；均P 18F]F-FDG PET/CT和肠造影，诊断一致性良好(均κ = 0.73； P 68Ga]Ga-FAPI-04 PET/CT在识别cd相关并发症和肠系膜改变的检出率和灵敏度上优于其他成像方法。结论：[68Ga]Ga-FAPI-04 PET/CT可作为CD患者的一步、无创诊断选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Biology 医学-核医学

CiteScore

6.90

自引率

3.20%

发文量

审稿时长

3 months

期刊介绍： Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures. Some areas that are covered are: Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes. The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets. Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display. Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging. Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics. Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations. Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.